A detailed history of Virtus ETF Advisers LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 4,315 shares of PRTA stock, worth $65,674. This represents 0.04% of its overall portfolio holdings.

Number of Shares
4,315
Previous 4,236 1.86%
Holding current value
$65,674
Previous $87,000 17.24%
% of portfolio
0.04%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.73 - $24.79 $1,321 - $1,958
79 Added 1.86%
4,315 $72,000
Q2 2024

Aug 14, 2024

BUY
$19.54 - $26.15 $39,334 - $52,639
2,013 Added 90.55%
4,236 $87,000
Q1 2024

May 15, 2024

SELL
$24.75 - $40.66 $3,712 - $6,098
-150 Reduced 6.32%
2,223 $55,000
Q4 2023

Feb 15, 2024

BUY
$32.31 - $52.32 $32,342 - $52,372
1,001 Added 72.96%
2,373 $86,000
Q3 2023

Nov 07, 2023

SELL
$47.3 - $70.6 $6,669 - $9,954
-141 Reduced 9.32%
1,372 $66,000
Q2 2023

Aug 14, 2023

SELL
$48.26 - $78.59 $11,099 - $18,075
-230 Reduced 13.2%
1,513 $103,000
Q1 2023

May 15, 2023

SELL
$46.97 - $58.27 $31,610 - $39,215
-673 Reduced 27.86%
1,743 $84,000
Q4 2022

Feb 14, 2023

SELL
$52.05 - $65.0 $111,439 - $139,165
-2,141 Reduced 46.98%
2,416 $145,000
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $855 - $2,061
34 Added 0.75%
4,557 $276,000
Q2 2022

Aug 12, 2022

BUY
$22.73 - $39.98 $19,025 - $33,463
837 Added 22.71%
4,523 $123,000
Q1 2022

May 16, 2022

SELL
$30.27 - $49.22 $6,508 - $10,582
-215 Reduced 5.51%
3,686 $135,000
Q4 2021

Feb 14, 2022

SELL
$42.11 - $73.26 $23,455 - $40,805
-557 Reduced 12.49%
3,901 $193,000
Q3 2021

Nov 15, 2021

SELL
$48.2 - $78.89 $11,375 - $18,618
-236 Reduced 5.03%
4,458 $318,000
Q2 2021

Aug 10, 2021

SELL
$21.63 - $57.65 $408,893 - $1.09 Million
-18,904 Reduced 80.11%
4,694 $241,000
Q1 2021

May 17, 2021

BUY
$11.0 - $28.24 $4,653 - $11,945
423 Added 1.83%
23,598 $593,000
Q4 2020

Feb 12, 2021

SELL
$10.12 - $13.94 $88,044 - $121,278
-8,700 Reduced 27.29%
23,175 $278,000
Q3 2020

Nov 13, 2020

SELL
$9.93 - $13.47 $43,175 - $58,567
-4,348 Reduced 12.0%
31,875 $318,000
Q2 2020

Aug 05, 2020

BUY
$9.56 - $12.51 $346,291 - $453,149
36,223 New
36,223 $379,000
Q4 2019

Feb 13, 2020

SELL
$7.48 - $17.01 $201,077 - $457,262
-26,882 Closed
0 $0
Q3 2019

Nov 12, 2019

SELL
$6.89 - $10.45 $10,314 - $15,643
-1,497 Reduced 5.28%
26,882 $211,000
Q2 2019

Aug 13, 2019

BUY
$8.85 - $12.49 $48,329 - $68,207
5,461 Added 23.83%
28,379 $300,000
Q1 2019

May 14, 2019

SELL
$10.32 - $14.49 $30,588 - $42,948
-2,964 Reduced 11.45%
22,918 $278,000
Q4 2018

Feb 05, 2019

SELL
$8.73 - $13.74 $47,639 - $74,979
-5,457 Reduced 17.41%
25,882 $267,000
Q3 2018

Nov 14, 2018

SELL
$12.7 - $15.79 $292,341 - $363,470
-23,019 Reduced 42.35%
31,339 $410,000
Q2 2018

Aug 10, 2018

BUY
$10.99 - $44.21 $372,582 - $1.5 Million
33,902 Added 165.73%
54,358 $793,000
Q1 2018

May 14, 2018

BUY
$27.95 - $45.04 $304,766 - $491,116
10,904 Added 114.15%
20,456 $751,000
Q4 2017

Feb 14, 2018

BUY
$35.44 - $63.76 $124,181 - $223,415
3,504 Added 57.94%
9,552 $358,000
Q3 2017

Nov 14, 2017

BUY
$53.83 - $67.75 $29,821 - $37,533
554 Added 10.08%
6,048 $392,000
Q2 2017

Aug 14, 2017

BUY
N/A
5,494
5,494 $297,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.